FDA News: Week of November 14, 2016

FDA approved


EndoCeutics Inc. Quebec, CANADA

INDICATION: Steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due to menopause.


  • Decline of estrogen during menopause cause condition known as VVA
  • Pain during sexual intercourse one of the most frequent symptoms of VVA
  • Need for treatment option forrelief of dyspareunia caused by VVA


  • Prasterone, also known as dehydroepiandrosterone (DHEA), included in some dietary supplements
  • Efficacy/safety of those products not established for diagnosing, curing, mitigating, treating or preventing disease

MECHANISM OF ACTION:  Inactive endogenous steroid  that is converted into active androgens and/or estrogens; mechanism of action not fully established.


  • Four 12-week placebo-controlled trials and one 52-week open-label trial; INTRAROSA vs. placebo
  • 4 co-primary endpoints: most bothersome moderate to severe symptom of dyspareunia, the percentage of vaginal superficial cells, the percentage of parabasal cells, and vaginal pH
  • Overall, reduced severity of pain experienced during sexual intercourse

SAFETY: Most common adverse reactions: vaginal discharge, abnormal Pap smear


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account.
Log Out / 
Change )

Google photo

You are commenting using your Google account.
Log Out / 
Change )

Twitter picture

You are commenting using your Twitter account.
Log Out / 
Change )

Facebook photo

You are commenting using your Facebook account.
Log Out / 
Change )

Connecting to %s